Aarti Industries Ltd
Aarti Industries Ltd, the flagship company of the Aarti group, manufacturing organic and inorganic chemicals at its major facilities in Vapi, Jhagadia, Dahej and Kutch, in Gujarat and in Tarapur in Maharashtra. The company has a strong market position in the NCB-based specialty chemicals segment.[1]
- Market Cap ₹ 15,432 Cr.
- Current Price ₹ 426
- High / Low ₹ 770 / 423
- Stock P/E 34.8
- Book Value ₹ 150
- Dividend Yield 0.23 %
- ROCE 7.47 %
- ROE 8.22 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 2.83 times its book value
- Promoter holding has decreased over last quarter: -0.63%
- The company has delivered a poor sales growth of 8.86% over past five years.
- Tax rate seems low
- Company might be capitalizing the interest cost
- Dividend payout has been low at 12.0% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of Nifty Smallcap 50 Nifty Smallcap 250 Nifty Smallcap 100 BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,086 | 2,619 | 2,890 | 3,006 | 3,163 | 3,806 | 4,168 | 4,186 | 4,506 | 6,086 | 6,619 | 6,372 | 6,988 | |
1,725 | 2,217 | 2,424 | 2,434 | 2,509 | 3,106 | 3,202 | 3,209 | 3,525 | 4,365 | 5,530 | 5,391 | 5,944 | |
Operating Profit | 361 | 402 | 466 | 572 | 654 | 700 | 965 | 977 | 982 | 1,720 | 1,089 | 982 | 1,044 |
OPM % | 17% | 15% | 16% | 19% | 21% | 18% | 23% | 23% | 22% | 28% | 16% | 15% | 15% |
4 | 11 | 9 | 6 | 2 | 7 | 2 | 9 | 1 | 1 | 1 | 3 | 21 | |
Interest | 95 | 118 | 138 | 117 | 117 | 132 | 183 | 125 | 86 | 102 | 168 | 211 | 239 |
Depreciation | 83 | 89 | 82 | 98 | 123 | 146 | 163 | 185 | 231 | 246 | 310 | 378 | 405 |
Profit before tax | 187 | 206 | 255 | 363 | 416 | 429 | 622 | 676 | 665 | 1,372 | 611 | 395 | 421 |
Tax % | 29% | 26% | 24% | 26% | 21% | 19% | 19% | 19% | 19% | 14% | 11% | -5% | |
135 | 163 | 208 | 268 | 328 | 346 | 504 | 547 | 535 | 1,186 | 545 | 416 | 445 | |
EPS in Rs | 4.25 | 4.58 | 5.81 | 7.71 | 9.62 | 10.24 | 14.18 | 15.39 | 15.02 | 32.71 | 15.04 | 11.49 | 12.27 |
Dividend Payout % | 24% | 25% | 24% | 28% | 3% | 2% | 19% | 11% | 10% | 11% | 17% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 9% |
3 Years: | 12% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -3% |
3 Years: | -7% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 3% |
3 Years: | -20% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 16% |
3 Years: | 16% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 40 | 44 | 44 | 42 | 41 | 41 | 43 | 87 | 87 | 181 | 181 | 181 | 181 |
Reserves | 717 | 826 | 972 | 1,096 | 1,321 | 1,538 | 2,587 | 2,892 | 3,416 | 4,335 | 4,739 | 5,109 | 5,262 |
849 | 1,039 | 1,202 | 1,292 | 1,564 | 2,083 | 2,401 | 2,098 | 2,857 | 2,587 | 2,907 | 3,242 | 3,883 | |
571 | 760 | 719 | 538 | 573 | 730 | 826 | 1,256 | 1,282 | 748 | 754 | 1,084 | 1,212 | |
Total Liabilities | 2,176 | 2,670 | 2,938 | 2,966 | 3,499 | 4,391 | 5,858 | 6,332 | 7,642 | 7,851 | 8,581 | 9,616 | 10,538 |
674 | 826 | 967 | 1,246 | 1,697 | 1,998 | 2,147 | 2,468 | 3,593 | 3,595 | 4,861 | 5,649 | 5,917 | |
CWIP | 69 | 117 | 193 | 313 | 270 | 436 | 795 | 1,418 | 1,298 | 1,346 | 1,096 | 1,229 | 1,393 |
Investments | 95 | 117 | 139 | 41 | 47 | 47 | 33 | 37 | 64 | 28 | 17 | 23 | 36 |
1,338 | 1,609 | 1,639 | 1,366 | 1,486 | 1,910 | 2,884 | 2,409 | 2,688 | 2,882 | 2,607 | 2,714 | 3,192 | |
Total Assets | 2,176 | 2,670 | 2,938 | 2,966 | 3,499 | 4,391 | 5,858 | 6,332 | 7,642 | 7,851 | 8,581 | 9,616 | 10,538 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
230 | 315 | 340 | 574 | 470 | 335 | 736 | 1,102 | 873 | 519 | 1,319 | 1,204 | |
-229 | -291 | -298 | -452 | -529 | -610 | -797 | -1,124 | -1,322 | -1,169 | -1,330 | -1,310 | |
1 | -22 | -23 | -128 | 58 | 279 | 833 | -535 | 614 | 412 | 38 | 35 | |
Net Cash Flow | 2 | 2 | 19 | -7 | -0 | 4 | 772 | -557 | 165 | -239 | 27 | -71 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 75 | 62 | 55 | 64 | 61 | 63 | 68 | 66 | 64 | 65 | 52 | 47 |
Inventory Days | 150 | 147 | 123 | 108 | 136 | 144 | 152 | 174 | 190 | 143 | 115 | 122 |
Days Payable | 74 | 90 | 55 | 67 | 71 | 69 | 55 | 72 | 117 | 53 | 24 | 55 |
Cash Conversion Cycle | 152 | 119 | 123 | 105 | 125 | 138 | 165 | 168 | 137 | 155 | 143 | 114 |
Working Capital Days | 120 | 99 | 91 | 96 | 93 | 103 | 99 | 93 | 63 | 120 | 95 | 82 |
ROCE % | 20% | 18% | 19% | 20% | 19% | 16% | 18% | 15% | 13% | 22% | 10% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
15 Nov - Transcript of Analyst and Investor Meet 2024
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 15 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Publication of audited financial results for Q2 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
8 Nov - Audio recording of Analyst and Investor meet uploaded.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
8 Nov - Analyst meet presentation on Q2 FY25 and H1 FY25 highlights.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT REC
-
Mar 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jul 2019TranscriptNotesPPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
Jun 2016Transcript PPT
-
Apr 2016TranscriptNotesPPT
-
Mar 2016TranscriptNotesPPT
-
Mar 2016TranscriptNotesPPT
-
Feb 2016Transcript PPT
-
Jan 2016TranscriptNotesPPT
Business Overview:[1]
Company manufactures speciality chemicals in Benzene based derivatives. Key value chains include Nitro Chloro Benzenes (NCBs), Di-Chloro Benzenes (DCBs), Phenylenediamines (PDAs), Nitro Toluene Value Chain and Equivalent Sulphuric Acid (E.S.A) & downstream.
Company has 16 manufacturing units, 2 R&D centres, 5 co-gen power plants, 100+ products, 700+ domestic customers, 400+ export customers in 60+ countries with major presence in the USA, Europe, Japan, etc.